Market Overview

Cowen Analyst Responds Following Amicus' Positive Migalastat News

Share:
Cowen Analyst Responds Following Amicus' Positive Migalastat News

Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) soared higher by more than 25 percent on Tuesday in reaction to the company's announcement that there is now a clear path to approval for its migalastat NDA therapy.

Amicus suffered a major setback for its therapy in November, 2016 when the U.S. Food and Drug Administration said it won't consider approving migalastat until the company provides more data in a process that could take up to four years to complete.

tipranks.png

But now the FDA reversed its prior position and is open to reviewing migalastat with existing dataset, Cowen's Ritu Baral commented in a research report. The FDA's position change is likely driven by the agency's commission Scott Gottlieb "new more practical/flexible" approach to the regulatory process, which bodes well for rare disease drug reviews.

The FDA's new approach of reviewing the totality of the clinical data which has been generated by Amicus to date implies there is a "good chance" the company's planned new drug approval in the fourth quarter of 2017 will be a success.

Meanwhile, Amicus believes there are around 3,000 diagnosed Fabry patients in the U.S. and can grow by up to 10 percent annually due to better awareness and diagnosis rates, the analyst added. Finally, total peak sales of $357 million is based on a conservative estimate.

At time of publication, shares of Amicus were up 27.29 percent on the day at $13.06.

Related Links:

Mid-Day Market Update: Halcon Resources Jumps After Announcing Sale of Williston Basin Assets; Shiloh Industries Shares Slide

12 Biggest Mid-Day Gainers For Tuesday

Latest Ratings for FOLD

DateFirmActionFromTo
Apr 2019Initiates Coverage OnBuy
Jan 2019Initiates Coverage OnOverweight
Jan 2019UpgradesNeutralBuy

View More Analyst Ratings for FOLD
View the Latest Analyst Ratings

Posted-In: AmicusAnalyst Color Biotech News FDA Analyst Ratings Movers General Best of Benzinga

 

Related Articles (FOLD)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
REALDA DavidsonInitiates Coverage On22.0
RVLVDA DavidsonInitiates Coverage On19.0
SFIXDA DavidsonInitiates Coverage On27.0
CONNKeyBancDowngrades
PENNJP MorganMaintains29.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

AMD's RX Vega Vs. Nvidia's GTX1080: The Great Rivalry Heats Up

Michael Kors Lower After Analyst Initiates Sell Rating